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yocardial Injury by Atorvastatin Is
ssociated With Lower Levels of Adhesion
olecules After Percutaneous Coronary Intervention
esults From the ARMYDA-CAMs (Atorvastatin for Reduction of
Yocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy
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OBJECTIVES The goal of this work was to investigate whether protection from myocardial injury during
percutaneous coronary intervention (PCI) by atorvastatin is related to reduction of endothelial
inflammatory response.
BACKGROUND In the randomized ARMYDA (Atorvastatin for Reduction of MYocardial Damage during
Angioplasty) trial, 7-day pre-treatment with atorvastatin before PCI significantly reduced
procedural myocardial injury; mechanisms underlying this effect are not characterized.
METHODS In a planned subanalysis of the ARMYDA trial, a subgroup of 76 patients was blind-tested
for measurement of plasma levels of vascular cell adhesion molecule-1 (VCAM-1), intercel-
lular cell adhesion molecule-1 (ICAM-1), and E-selectin: 38 patients belonged to atorva-
statin (40 mg/day) and 38 to the placebo arm. Adhesion molecules were evaluated 7 days
before intervention, immediately before PCI, and after 8 and 24 h.
RESULTS Reduction of procedural myocardial injury after statin pre-treatment was also confirmed in
this subgroup. Intercellular cell adhesion molecule-1, E-selectin, and VCAM-1 levels were
not different at randomization and before intervention in either arm. At 8 h, increase of
ICAM-1 levels was similar in the 2 arms, whereas 24-h levels were significantly lower in the
atorvastatin versus placebo group (282  56 vs. 325  70 ng/ml; p  0.007). Attenuation of
E-selectin elevation occurred at 8 h in the atorvastatin group (50  8 vs. 59  13 ng/ml; p 
0.002) and became even more significant at 24 h (57  9 vs. 73  18 ng/ml; p  0.0008).
Vascular cell adhesion molecule-1 levels were not different at any time point in the 2
arms.
CONCLUSIONS In patients undergoing PCI, reduction of procedural myocardial injury after 7-day pre-
treatment with atorvastatin is paralleled by concomitant attenuation of post-procedural
increase of ICAM-1 and E-selectin levels; thus, reduction of endothelial inflammatory
response may explain this protective effect of statins. (J Am Coll Cardiol 2006;48:1560–6)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.061© 2006 by the American College of Cardiology Foundation
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pptimization of periprocedural pharmacologic therapy has
crucial role in patients undergoing percutaneous coronary
ntervention, influencing occurrence of early cardiac events
1,2). In the randomized ARMYDA (Atorvastatin for
eduction of MYocardial Damage during Angioplasty) trial
1), pre-treatment with atorvastatin 40 mg/day initiated 7
ays before percutaneous intervention in patients with stable
ngina was associated with 80% risk reduction of peripro-
edural myocardial infarction. The mechanisms underlying
his protective action are unknown, but are possibly due to
he pleiotropic effects of statins; this class of drugs may, in
act, have anti-inflammatory effects by influencing cytokines
nd growth-factors release (3), may decrease apoptosis (4),
From the *Department of Cardiovascular Sciences, Campus Bio-Medico Univer-
ity, Rome, Rome, Italy; the †Interventional Cardiology Unit, San Filippo Neri
ospital of Rome, Rome, Italy; and the ‡Second University of Naples, Naples, Italy.p
Manuscript received May 10, 2006; revised manuscript received June 19, 2006,
ccepted June 26, 2006.mprove endothelial function (5), reduce adhesion molecules
xpression and adhesiveness of leucocytes to vascular endothe-
ium (6,7), and have direct protective effects on myocardial cells
8); these actions may be independent of low-density lipopro-
ein reductions.
A planned subgroup analysis was prospectively performed
mong patients enrolled in the ARMYDA trial to investigate
hether pre-treatment with atorvastatin reduces procedural
yocardial damage by mechanisms linked to reduction of
nflammatory endothelial activation (ARMYDA-CAMs
Atorvastatin for Reduction of MYocardial Damage during
ngioplasty-Cell Adhesion Molecules] substudy); in particu-
ar, the study was designed to evaluate whether variations in the
ost-procedural levels of soluble adhesion molecules (vascular
ell adhesion molecule-1 [VCAM-1], intercellular cell adhe-
ion molecule-1 [ICAM-1], and E-selectin) are influenced by
re-treatment with atorvastatin in patients undergoing elective
ercutaneous coronary intervention.
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atient population and study design. The main ARMYDA
tudy was a randomized, multicenter, prospective, double-
lind, placebo-controlled trial (1). Patients with stable
ngina, significant coronary artery disease, and an indication
o elective coronary angioplasty were enrolled. The study
ncluded 153 patients from 2 institutions randomized to
Abbreviations and Acronyms
ARMYDA  Atorvastatin for Reduction of
MYocardial Damage during
Angioplasty
ARMYDA-CAMs  Atorvastatin for Reduction of
MYocardial Damage during
Angioplasty-Cell Adhesion
Molecules substudy
CRP  C-reactive protein
ICAM-1  intercellular cell adhesion
molecule-1
VCAM-1  vascular cell adhesion molecule-1
igure 1. Design of the ARMYDA-CAMs (Atorvastatin for Reduction o
AMs  cell adhesion molecules; CK-MB  creatine kinase-MB; CRP 
CI  percutaneous coronary intervention; VCAM-1  vascular cell adhesiontorvastatin (40 mg/day, n  76) or placebo (n  77)
tarting 7 days before planned percutaneous revasculariza-
ion. The ARMYDA-CAMs was designed as a prospective
ubstudy of the main trial to be performed in all patients
nrolled at a single institution (Campus Bio-Medico Uni-
ersity of Rome). Inclusion and exclusion criteria were the
ame as the original ARMYDA trial (1), although patients
ere required to give an additional specific informed con-
ent for participation to the ARMYDA-CAMs. Thus, the
tudy included all 76 consecutive patients enrolled at Cam-
us Bio-Medico University: 38 were randomized to atorva-
tatin and 38 to placebo. Vascular cell adhesion molecule-1,
CAM-1, and E-selectin plasma levels were blindly mea-
ured at randomization (i.e., 7 days before intervention),
mmediately before the procedure, and after 8 and 24 h (Fig.
). According to the design of the ARMYDA trial, blood
amples were also drawn before intervention and at 8 and
4 h after the procedure to assay creatine kinase-MB
mass), troponin-I (mass), myoglobin, and C-reactive
rotein (CRP) levels.
ocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.f MY
C-reactive protein; ICAM-1  intercellular cell adhesion molecule-1;
molecule-1.
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Statins and Adhesion Molecules After PCI October 17, 2006:1560–6All interventions were performed via the femoral ap-
roach with standard technique, as previously described (1).
weight-adjusted dose of heparin (100 IU/kg) was given in
he catheterization laboratory before the procedure. Blood
amples for adhesion molecule determinations were col-
ected in EDTA-K3 syringes and immediately centrifuged
t 10°C (5 min, 3,000  g), and the plasma was stored at
70°C until analysis. Soluble adhesion molecules
CAM-1, ICAM-1, and E-selectin were assessed by blind
nvestigators using a double primary antibody sandwich
nzyme-linked immunoabsorbant assay (R&D Systems,
bingdon, United Kingdom). The test is based on simul-
aneous reaction of the adhesion molecule to 2 monoclonal
ntibodies directed against different epitopes on the adhe-
ion molecule. All assays are standardized against purified
orms of recombinant VCAM, ICAM, or E-selectin. In our
aboratory, sensitivity (minimal detectable dose) for
CAM-1 is lower than 2.0 ng/ml, for ICAM-1 it is lower
han 0.35 ng/ml, and for E-selectin it is lower than 1.0
g/ml. There was no cross-reactivity with other adhesion
olecules. Dilution curves of the serum samples were
arallel to standard dilution curves. The inter-assay and
ntra-assay coefficients of variation were 8%, as deter-
ined in human serum. Measurements of creatine kinase-
B, troponin-I, and myoglobin levels were performed
sing the Access 2 Immunochemiluminometric assay
Beckman Coulter, Fullerton, California) (9). Upper normal
imits were defined as the 99th percentile of normal popu-
ation with a total imprecision of 10%, according to Joint
uropean Society of Cardiology/American College of Car-
iology guidelines (10). Normal limits were 4 ng/ml for
reatine-kinase MB, 0.08 ng/ml for troponin-I, and 80
g/ml for myoglobin. High-sensitivity CRP determination
as obtained by the KRIPTOR-ultrasensitive immunoflu-
rescent assay (BRAHMS, Hennigsdorf/Berlin, Germany),
ith a detection limit of 0.06 mg/l.
The primary end point of the ARMYDA-CAMs sub-
tudy was to compare changes of adhesion molecule levels
fter coronary interventions according to pre-treatment with
torvastatin or placebo. The secondary end point was the
orrelation of such levels to the occurrence of procedural
yocardial damage.
The study was approved by the institutional review board
f our institution and was not supported by any external
ource of funding.
tatistics. Values are expressed as mean  SD, unless
therwise specified. Non-parametric Friedman analysis of
ariance for repeated measures followed by pairwise com-
arisons (Wilcoxon signed rank test with Bonferroni’s
djustment for the 3 comparisons of adhesion molecule
evels at each time point) was applied to detect changes in
CAM-1, ICAM-1, and E-selectin levels over time within
he same group (atorvastatin or placebo). The Mann-
hitney U test was used to compare continuous data
etween the 2 arms; proportions were compared by Fisher
xact test when the expected frequency was 5; otherwise,
ehe chi-square test (Yates’ corrected) was applied. Correla-
ions between variables were assessed by Spearman’s rank
est. All calculations were performed by SPSS 12.0 (SPSS
nc., Chicago, Illinois), and p values 0.05 (2-tailed) were
onsidered significant.
ESULTS
tudy population. Clinical and procedural data of the
RMYDA-CAMs population are indicated in Tables 1
nd 2, respectively. The 2 randomization arms were similar
or age, gender, cardiovascular risk factors, clinical presen-
ation (all patients had stable angina by protocol design), left
entricular function, serum creatinine levels, and medical
herapy at the time of intervention. Coronary anatomy,
rocedural characteristics, use of drug-eluting stents, diam-
ter and length of implanted stents, and use of glycoprotein
Ib/IIIa inhibitors were also similar. Procedural success was
btained in all 76 patients; no patient had no-reflow
henomenon or significant (2 mm) side branch closure
uring the intervention. There were no in-hospital major
omplications (death or need for urgent revascularization).
rimary end point. Intercellular cell adhesion molecule-1,
-selectin, and VCAM-1 levels drawn at the time of
andomization were similar in both arms (Fig. 2).
Intercellular cell adhesion molecule-1 levels did not
hange during the 7 days of pre-treatment in either arm
atorvastatin 216 40 ng/ml, placebo 204 38 ng/ml, p
.07). At 8 h post-procedure, the levels rose significantly
rom baseline, in a similar fashion in both groups (atorva-
tatin 243 46 ng/ml, placebo 239 43 ng/ml;12 9%
s. 17  14%; p  0.1 for groups comparison) (Figs. 2
nd 3); at 24 h this increase was significantly lower in the
able 1. Clinical Characteristics in the Placebo and Atorvastatin
roups
Variable
Placebo
(n  38)
Atorvastatin
(n  38)
p
Value
ale gender 34 (90) 34 (90) 0.71
ge (yrs) 65  11 64  11 0.74
iabetes mellitus 8 (21) 10 (26) 0.79
ystemic hypertension 28 (74) 29 (76) 1
ypercholesterolemia 16 (42) 17 (45) 1
urrent smokers 7 (18) 11 (29) 0.42
amily history of coronary artery
disease
5 (13) 8 (21) 0.54
revious myocardial infarction 7 (18) 9 (24) 0.78
revious coronary intervention 4 (11) 4 (11) 1*
revious bypass surgery 2 (5) 4 (11) 0.67*
eft ventricular ejection fraction (%) 54  9 54  10 0.72
ultivessel coronary artery disease 8 (21) 7 (18) 1
erum creatinine (mg/dl) 1.1  0.4 1.1  0.3 0.85
spirin 37 (97) 38 (100) 1
iclopidine/clopidogrel 38 (100) 38 (100) —
eta-blockers 13 (34) 13 (34) 0.81
CE inhibitors 24 (63) 24 (63) 0.81
alues are given as n (%) or mean  SD. *Indicates p values obtained with Fisher
xact test.
ACE  angiotensin-converting enzyme.
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October 17, 2006:1560–6 Statins and Adhesion Molecules After PCItorvastatin versus placebo arm (282  56 vs. 325  70
g/ml, p  0.007; 30  6% vs. 59  9%, p  0.0001).
As illustrated in Figure 2, E-selectin levels before inter-
ention were also similar in the 2 arms (atorvastatin 40  9
g/ml, placebo 41  10 ng/ml, p  0.72) and increased
ignificantly after the procedure. Unlike ICAM-1 levels, a
ignificant attenuation of E-selectin rise was already ob-
erved at 8 h in the atorvastatin group versus placebo (50 
vs. 59  13 ng/ml, p  0.002; 25  5% vs. 44  8%
rom baseline, p  0.0001); this became even more signif-
cant at 24 h (57  9 vs. 73  18 ng/ml, p  0.0008;
42  9% vs. 78  18%, p  0.0001) (Figs. 2 and 3).
Vascular cell adhesion molecule-1 levels increased
ignificantly from baseline at 8 and 24 h, but no differ-
nces at any time point were observed between the 2 arms
Figs. 2 and 3).
Low-density lipoprotein levels after the 1-week pre-
reatment were not different in the 2 groups (atorvastatin
20  28 mg/dl; placebo 125  30 mg/dl, p  0.39); no
orrelation was found between lipid levels and circulating
evels of adhesion molecules (p  0.40).
rocedural myocardial injury. In agreement with the re-
ults obtained in the global ARMYDA population, in this
ubset of patients myocardial infarction (defined as post-
rocedural creatine kinase-MB increase 2 above the
pper normal limit) occurred in 5% of patients in the
torvastatin versus 21% of those in the placebo group (p 
.08); any elevation of creatine kinase-MB above normal
imits was detected in 11% of patients in the atorvastatin
Table 2. Procedural Characteristics
Variables
Vessel treated
Left anterior descending
Left circumflex
Right coronary artery
Saphenous vein grafts
Restenotic lesions
Lesion type B2/C
Chronic total occlusions (3 months)
Multivessel intervention
Type of intervention
Balloon only
Stent
Stent plus rotablator/atherectomy
Bifurcations with kissing balloon
No. of stents per patient 1
Stent diameter (mm) 3
Total stent length (mm) 2
Use of drug-eluting stents
Direct stenting
No. of pre-dilatations
Stent deployment pressure (atm) 1
Duration of stent deployment (s)
Total ischemia 120 s
Use of post-dilatation
Use of glycoprotein IIb/IIIa inhibitors
Values are given as n (%) or mean  SD. *Indicates p valuerm (vs. 34% in the placebo arm; p  0.028); similarly, the aroportions of patients with troponin-I (18% vs. 45%; p 
.026) and myoglobin increases (21% vs. 47%; p  0.030)
ere significantly lower.
According to the secondary end point, post-procedural
dhesion molecule peak levels were also correlated to occur-
ence of procedural myocardial damage, defined as
roponin-I elevation above normal limits after intervention.
s illustrated in Figure 4, patients with E-selectin levels
elow the median (67 ng/ml) had a significantly lower
ncidence of myocardial damage in the atorvastatin versus
he placebo arm (3% vs. 21%, p  0.03). No significant
ncrease in E-selectin levels was observed in patients of
ither arm with procedural myocardial damage (p  0.33).
imilar findings were obtained with ICAM-1 determina-
ions (data not shown).
C-reactive protein levels at the time of the procedure
ere not different (2.4  2.4 mg/l in the treatment vs.
.3  13.8 mg/l in the placebo group, p 0.54). There was
non-significant trend toward attenuation of 8-h post-
rocedural increase of CRP values in patients randomized to
torvastatin (3.1  2.5 vs. 7.4  13.9 mg/l, p  0.10),
hereas 24-h CRP levels were not significantly different
etween the 2 groups (3.7  2.7 vs. 7.5  14.1 mg/l, p 
.78).
ISCUSSION
he ARMYDA-CAMs substudy shows that 7 days of
re-treatment with atorvastatin of patients with stable
bo
38)
Atorvastatin
(n  38) p Value
3) 19 (50) 1
1) 8 (21) 0.89
6) 10 (26) 0.79
1 (3) 1*
) 1 (3) 1*
1) 26 (68) 1
) 3 (8) 1*
3) 5 (13) 0.73
) 2 (5) 1*
4) 35 (92) 1
) 1 (3) 1*
) 4 (11) 1
0.9 1.40  0.8 0.59
0.6 3.16  0.4 0.98
9 24.1  10 0.25
1) 5 (13) 0.54
6) 9 (24) 1
2.0 1.9  2.1 0.26
2.4 13.5  1.9 0.82
6 30  6 0.21
6) 8 (21) 0.77
8) 9 (24) 0.78
6) 9 (24) 0.56
ined with Fisher exact test.Place
(n 
20 (5
8 (2
10 (2
—
1 (3
27 (7
2 (5
5 (1
1 (3
36 (9
1 (3
3 (8
.35 
.15 
1.0 
8 (2
10 (2
1.6 
3.7 
29 
6 (1
7 (1
6 (1ngina significantly attenuates the increase in levels of
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Statins and Adhesion Molecules After PCI October 17, 2006:1560–6dhesion molecules after coronary intervention; these find-
ngs suggest that this effect may contribute to the procedural
yocardial protection provided by atorvastatin, first de-
igure 2. Soluble intercellular cell adhesion molecule-1 (ICAM-1, top),
-selectin (middle), and vascular cell adhesion molecule-1 (VCAM-1,
ottom) levels in the 2 arms at randomization (i.e., 7 days before
ntervention), at the time of intervention, after 8 and 24 h. The Wilcoxon
igned rank test with Bonferroni’s correction for the comparisons between
ime points in both arms showed a significant rise from baseline of
CAM-1, E-selectin, and VCAM-1 levels (p  0.01) in all post-
rocedural determinations. This increase was significantly lower in the
torvastatin versus placebo arm at 8 and 24 h for E-selectin and at 24 h for
CAM-1. Data are mean  SEM. PCI  percutaneous coronary inter-
ention. White bars  atorvastatin; black bars  placebo.cribed in the ARMYDA trial (1).
V
bAdhesion molecules are expressed on the membrane of
ctivated cells, representing specific surface receptors for
nteraction between leukocytes and endothelial cells (11–
3). Soluble circulating forms of adhesion molecules can be
easured from peripheral blood samples, and their levels
eflect the amount of membrane-bound adhesion molecules
nd the degree of local endothelial activation (14). Previous
tudies on small numbers of patients have shown that
oronary angioplasty is followed by a transient increase in
dhesion molecule levels (15) due to local endothelial
ctivation/damage (16). Our results confirm and expand
hese findings by showing, in a larger number of patients,
hat percutaneous intervention is invariably followed by an
ncrease in adhesion molecule levels, in agreement with the
ctivation kinetics of these molecules (13) (although the
bsence of measurements beyond the 24 h does not allow
valuation of their decrease pattern).
Anti-inflammatory actions of statins are recognized, but
tudies on the effects of these drugs on adhesion molecule
oncentrations in subjects with hypercholesterolemia
ielded controversial results (17–19); to date, no previous
tudy has assessed the effect of short-term treatment with
tatins on adhesion molecule levels in patients undergoing
ercutaneous coronary intervention. In keeping with previ-
us experimental data showing that statins do not influence
aseline expression of adhesion molecules in vitro (20), in
ur study atorvastatin 40 mg/day for 1 week did not modify
aseline levels of soluble adhesion molecules. However,
tatins were demonstrated to decrease CAM expression
fter different inflammatory stimuli (including tumor necro-
is factor-alpha, lipopolysaccharide, interferon-gamma or
RP) (6,21–23). Recent data from our institution (24)
howed that pre-treatment with simvastatin significantly
ecreases post-operative ICAM-1 and E-selectin elevations
fter coronary bypass surgery; likewise, the ARMYDA-
AMs study now suggests a drug-mediated attenuation of
igure 3. Post-procedural 24-h percent increase from baseline of adhesion
olecule levels. ICAM-1  intercellular cell adhesion molecule-1;
CAM-1 vascular cell adhesion molecule-1. White bars atorvastatin;
lack bars  placebo.
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October 17, 2006:1560–6 Statins and Adhesion Molecules After PCIhe adhesion molecules increase after the inflammatory
timulus represented by percutaneous coronary intervention.
The protective effects of atorvastatin on myocardial dam-
ge during coronary intervention observed in the main
andomized ARMDYDA trial (1) has been confirmed in
he subpopulation of the present study. The mechanism(s)
nderlying this clinical benefit are not clear; the
RMYDA-CAMs substudy shows a significant decrease of
ost-intervention levels especially of E-selectin, expressed
y endothelial cells; thus, attenuation of endothelial activa-
ion may, at least in part, explain the protective role of
torvastatin. In fact, patients of the atorvastatin arm with
ower post-procedural CAM levels had a significantly less
ncidence of myocardial damage, suggesting that reduction
f adhesion molecule release may help prevent myocardial
amage by limiting local recruitment of inflammatory cells,
y improving small vessel function (25), and, possibly, by
tabilizing coronary plaque and reducing microemboliza-
ion. Another explanation of the parallelism between endo-
helial activation and myocardial injury is that both these
ndings could be an expression of a common mechanism of
rotection induced (or potentiated) by statin therapy (i.e.,
ncreased nitric oxide bioavailability). It may be also argued
hat the attenuation in the increase in CAMs may be due to
he lower micro-infarct rate (i.e., inflammation due to
icro-infarcts causes an elevation in CAMs, and a lower
nfarct rate may lead to lower CAMs). However, no
ignificant increase of adhesion molecule levels was observed
n patients of either arm with procedural myocardial dam-
ge, and atorvastatin significantly attenuated CAM levels
rrespective of the occurrence of myocardial damage. These
esults would support the hypothesis that the beneficial
ffect of atorvastatin is indeed due to attenuation in the
ncrease of adhesion molecules, and that procedural myo-
ardial necrosis was not a significant effect modifier that
igure 4. (A) Incidence of procedural myocardial damage in patients of b
67 ng/ml, median value; high E-selectin: 67 ng/ml). (B) Post-procedur
yocardial damage (defined as post-procedural troponin-I elevation aboverives the results.In our study, atorvastatin did not affect post-procedural
CAM-1 levels; this was also observed in a previous study
f different design, not involving coronary intervention,
fter prolonged therapy with statins (19). Indeed, although
ommon regulatory mechanisms have been recognized,
ifferent factors may be involved in the regulation of
dhesion molecules on different cell types (26). Moreover,
re-treatment with atorvastatin was not associated with
ignificant attenuation of CRP levels before and after
ntervention; in fact, effects of statins on adhesion molecules
ay be independent from CRP (27) or may precede
ystemic cytokine cascade activation (5).
In conclusion, the ARMYDA-CAMs substudy shows
hat pre-treatment with atorvastatin reduces myocardial
amage and adhesion molecule levels after coronary angio-
lasty. These findings may help clarify the mechanisms
nderlying myocardial protection provided by statin therapy
efore percutaneous coronary interventions, as well as the
iological basis of the pleiotropic effects of statins.
eprint requests and correspondence: Dr. Germano Di Sciascio,
epartment of Cardiovascular Sciences, Campus Bio-Medico
niversity, Via E. Longoni, 83, 00155 Rome, Italy. E-mail:
.disciascio@unicampus.it.
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